This Little-Known Stock Just Doubled on Weight-Loss Drug News. Analysts Think It Has 400% Upside Potential From Here.
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Allurion Stock Skyrockets 80% After Hours Following Clinical Study Announcement
In one research, over four months participants on the Allurion Program showed a 14% drop in overall weight and a 5.6% gain in lean body mass. Another trial revealed a 15.7% weight decrease devoid of ...
Business Wire6d
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less TM gastric balloon for weight loss, the Allurion ...
Morningstar6d
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase ...
Allurion Technologies stock soars on clinical study announcement
Investing.com -- Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% following the company's announcement of its plans to initiate a clinical study aimed at optimizing muscle mass during ...
Investing6d
Allurion Technologies stock soars on clinical study announcement
which includes the Allurion Gastric Balloon, the first swallowable, procedure-less gastric balloon for weight loss, and a comprehensive virtual care suite. The virtual care offering is designed to ...